498 related articles for article (PubMed ID: 11876753)
1. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.
Lytton SD; Berg U; Nemeth A; Ingelman-Sundberg M
Clin Exp Immunol; 2002 Feb; 127(2):293-302. PubMed ID: 11876753
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics.
Lytton SD; Helander A; Zhang-Gouillon ZQ; Stokkeland K; Bordone R; Aricò S; Albano E; French SW; Ingelman-Sundberg M
Mol Pharmacol; 1999 Feb; 55(2):223-33. PubMed ID: 9927612
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
Miyakawa H; Kitazawa E; Kikuchi K; Fujikawa H; Kawaguchi N; Abe K; Matsushita M; Matsushima H; Igarashi T; Hankins RW; Kako M
Autoimmunity; 2000; 33(1):23-32. PubMed ID: 11204250
[TBL] [Abstract][Full Text] [Related]
4. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.
Lecoeur S; André C; Beaune PH
Mol Pharmacol; 1996 Aug; 50(2):326-33. PubMed ID: 8700140
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
6. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a steroid-resistant transplant rejection episode.
Lohse AW; Obermayer-Straub P; Gerken G; Brunner S; Altes U; Dienes HP; Manns MP; Meyer zum Büschenfelde KH
J Hepatol; 1999 Jul; 31(1):149-55. PubMed ID: 10424295
[TBL] [Abstract][Full Text] [Related]
7. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
8. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
[TBL] [Abstract][Full Text] [Related]
9. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression.
Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimaräes S
Transplant Proc; 2000 Dec; 32(8):2636-8. PubMed ID: 11134735
[No Abstract] [Full Text] [Related]
10. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
12. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
13. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies of differentiating specificities as probes of cytochrome P450h (2C11).
Ryan DE; Thomas PE; Levin W; Maines SL; Bandiera S; Reik LM
Arch Biochem Biophys; 1993 Mar; 301(2):282-93. PubMed ID: 7681658
[TBL] [Abstract][Full Text] [Related]
15. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
[No Abstract] [Full Text] [Related]
16. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
20. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
